Who are Skyclarys's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BG00012 (DMF) (Tecfidera®.), Vumerity, BG00012 (DMF), BG00012 (dimethyl fumarate).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/omaveloxolone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Skyclarys — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Skyclarys (OMAVELOXOLONE) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

marketed Nuclear factor erythroid 2-related factor 2 Other Small molecule Live · refreshed every 30 min

Target snapshot

Skyclarys (OMAVELOXOLONE) — Biogen Us. Skyclarys works by activating the Nrf2 pathway to increase the production of antioxidant proteins that protect cells from damage.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Skyclarys TARGET	OMAVELOXOLONE	Biogen Us	marketed		Nuclear factor erythroid 2-related factor 2	2023-01-01
BG00012 (DMF) (Tecfidera®.)	BG00012 (DMF) (Tecfidera®.)	Multiple Sclerosis Center of Northeastern New York	marketed	Fumaric acid ester; Nrf2 activator	Nuclear factor erythroid 2-related factor 2 (Nrf2)
Vumerity	Vumerity	University of Nebraska	marketed		Nuclear factor erythroid 2-related factor 2, Hydroxycarboxylic acid receptor 2
BG00012 (DMF)	BG00012 (DMF)	Biogen	marketed	Fumaric acid ester; immunomodulator	Nrf2 (nuclear factor erythroid 2-related factor 2)
BG00012 (dimethyl fumarate)	BG00012 (dimethyl fumarate)	Biogen	phase 3	Fumaric acid ester; immunomodulator	Nrf2 (nuclear factor erythroid 2-related factor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Skyclarys — Competitive Intelligence Brief. https://druglandscape.com/ci/omaveloxolone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing